PFIZER IS MARKET ENERGIZER IN SECOND QUARTER: 42% JUMP LEADS WAY TO NEW VALUATION FOR Rx STOCKS; "F-D-C" PHARMACEUTICAL INDEX SOARS 27% FOR THREE MONTHS
Executive Summary
Pfizer has emerged as a Wall Street darling after a 42% run-up during the second quarter established the stock as the bellwether for a new -- and more precarious -- valuation level for the brandname pharmaceutical industry